ATTOVIA THERAPEUTICS
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
ATTOVIA THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2023-01-01
Address:
Fremont, California, United States
Country:
United States
Website Url:
http://www.attovia.com
Total Employee:
11+
Status:
Active
Total Funding:
165 M USD
Technology used in webpage:
Euro Google Maps CrUX Top 50m CrUX Dataset Google Maps API Google Maps For Work
Similar Organizations
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
Marshall Wace
Marshall Wace investment in Series B - Attovia Therapeutics
Redmile Group
Redmile Group investment in Series B - Attovia Therapeutics
Nextech Ventures
Nextech Ventures investment in Series B - Attovia Therapeutics
EcoR1 Capital
EcoR1 Capital investment in Series B - Attovia Therapeutics
Logos Capital
Logos Capital investment in Series B - Attovia Therapeutics
venBio Partners
venBio Partners investment in Series B - Attovia Therapeutics
Illumina Ventures
Illumina Ventures investment in Series B - Attovia Therapeutics
Goldman Sachs Asset Management
Goldman Sachs Asset Management investment in Series B - Attovia Therapeutics
Frazier Life Sciences
Frazier Life Sciences investment in Series B - Attovia Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Attovia Therapeutics
Official Site Inspections
http://www.attovia.com Semrush global rank: 9.82 M Semrush visits lastest month: 308
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Attovia Therapeutics"
Home - ATTOVIA
Prior to Attovia, Zaneta served full time at Frazier, focusing on company creation activities and advising on private and public investment opportunities. Before joining Frazier, Zaneta served on the Corporate Development team at Amunix …See details»
Attovia Therapeutics - Crunchbase Company Profile
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, …See details»
Our Team - ATTOVIA
Prior to Attovia, Zaneta served full time at Frazier, focusing on company creation activities and advising on private and public investment opportunities. Before joining Frazier, Zaneta served on the Corporate Development team at Amunix …See details»
Attovia Company Profile 2024: Valuation, Funding & Investors
Attovia General Information Description. Developer of biotherapeutics pipeline designed for immune-mediated disease and oncology. The company leverages the nanobody platform, to …See details»
Attovia Therapeutics - LinkedIn
Attovia has made immense progress in building a pipeline of strong programs leveraging the proprietary Attobodyâ„¢ biologics platform, with an initial focus on treating immune-mediated diseases ...See details»
Attovia, a new California biotech, launches with plans to rethink …
Jun 20, 2023 Attovia aims to "fine-tune" antibody components to make more selective medicines, Fu said. Essentially, Attovia will use nanobodies, or small antibody fragments, to …See details»
Attovia Therapeutics - Contacts, Employees, Board Members, …
Organization. Attovia Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Attovia Therapeutics has 1 current employee profile, Chief …See details»
Attovia Therapeutics Launches with $60 Million Series A Financing …
Jun 20, 2023 Tao Fu, M.S., M.B.A., co-founder of Attovia and Venture Partner at Frazier Life Sciences, will serve as Attovia’s chief executive officer and join the Board. Mr. Fu is a …See details»
Attovia Enhances Clinical and Development Expertise with …
Mar 26, 2024 -- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer -- Industry veterans and leading academic experts joined Attovia’s …See details»
Attovia Therapeutics Launches with $60 Million Series A Financing …
Jun 20, 2023 Company Formed by Alamar Biosciences and Frazier Life Sciences Attobodyâ„¢ Platform Generates Small Format Binders for Hard-to-drug Targets FREMONT, Calif. and …See details»
News & Media - ATTOVIA
Oct 15, 2024 Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives FREMONT, Calif., May 9, 2024 (GLOBE NEWSWIRE) — Attovia Therapeutics today announced the closing …See details»
Attovia Announces Second Tranche Closing of $60 Million Series A ...
Feb 8, 2024 Attovia also announced the nomination of the first development candidate generated from its Attobodyâ„¢ biologics platform, ATTO-1310, a potential first-in-class, long …See details»
Attovia Announces Second Tranche Closing of $60 Million
Feb 8, 2024 Attovia also announced the nomination of the first development candidate generated from its Attobodyâ„¢ biologics platform, ATTO-1310, a potential first-in-class, long …See details»
Attovia Therapeutics Launches with $60 Million Series A
Jun 20, 2023 Attovia will receive an exclusive world-wide license to the Attobody platform and associated intellectual property and pipeline assets in the therapeutic field in exchange for …See details»
Attovia Therapeutics Raises $105 Million Oversubscribed Series B ...
May 9, 2024 Attovia is advancing a pipeline of spatially optimized biparatopic biologics generated from its Attobodyâ„¢ platform. The Company’s lead programs, ATTO-1310, a …See details»
Attovia Therapeutics Raises $105 Million Oversubscribed Series B ...
FREMONT, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the closing of a $105 million oversubscribed Series B financing, bringing the total capital raised …See details»
Attovia secures $105m to advance lead programmes development
May 10, 2024 Attovia is also preparing to nominate a development candidate for ATTO-002 in late 2024 and aims to progress to IND next year. The company is advancing discovery-stage …See details»
Attovia Therapeutics Raises $105 Million Oversubscribed
May 9, 2024 Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages ATTOBODYâ„¢, a biparatopic biologics platform, …See details»
Science - ATTOVIA
Unleashing the power of ATTOBODY® technology to develop new medicines ATTOBODIES are biparatopic biologics; that is, each ATTOBODY binds to two different epitopes on the target …See details»
Pipeline - ATTOVIA
Pipeline attovia 2024-11-05T22:49:04+00:00. Our pipeline. We are advancing a broad pipeline of potentially best-in-class biotherapeutics, with initial focus on immune-mediated disease. Learn …See details»